Biotech Breakthroughs 2026 — QMA ranking
Leaders in GLP-1 (obesity), oncology, gene therapy. High volatility around clinical trials, but winners scale 10×+.
Biotech is a binary outcome sector — clinical trial results = 30-50% price moves. GLP-1 obesity drugs (Eli Lilly, Novo Nordisk) are rewriting healthcare.
This biotech breakthroughs ranking is assembled by the QMA analytical engine from the current composite score and this category's filters — sorted from the highest rating. Recomputed daily. It is not a backtest result. This is a descriptive analytical assessment, not investment advice.
Unlock the full screener, smart-money data layers (insider, 13F, off-exchange flow, options), model backtests and a daily analytical overview. Try QMA and watch how the rankings evolve over time.
QMA is an analytical and educational tool, not investment advice. The ranking is based on the current QMA composite score; past performance does not guarantee future results.
⚠️ Important Notice: QMA is an analytical and educational tool, not investment advice. Scores, detections and ratings are descriptive, not buy/sell instructions. QMA is not a registered investment advisor (SEC / FINRA / MiFID II / ČNB). Consult a licensed financial advisor before any investment. Past performance does not guarantee future results; all investments carry the risk of capital loss.
Operator: Jaroslav Vojtášek · IČO: 48783447 · Place of business: U Jízdárny 577, 747 64 Velká Polom, Czech Republic · Register: Sole trader registered in the Czech Trade Licensing Register · E-mail: [email protected]